Evidence map›Paper›PMID 41377559›Full record

ReviewFrontiers in nutrition2025

Traditional Chinese medicine monomers: a new strategy against diabetic kidney disease by regulating cholesterol efflux.

Chenguang Wu, Jianing Sun, Junwei Shi, Zhe Li, Yan An, Han Zhu, Lifan Wang, Peng Liu

Abstract readReview
In one paragraph

Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chenguang Wu *Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Jianing Sun *Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Junwei Shi *Renal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Zhe LiRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Yan AnRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Han ZhuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Lifan WangRenal Division, Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
Peng LiuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD), a prevalent microvascular complication of diabetes, is driven by a complex pathogenesis. A key pathological hallmark of early DKD is intrarenal lipid deposition, a process pivotally driven by impaired cholesterol efflux. This efflux is critically mediated by ATP-binding cassette (ABC) transporters, primarily ABCA1 and ABCG1. Dysfunction of these transporters precipitates cholesterol accumulation in renal cells, subsequently inducing oxidative stress, inflammation, and fibrosis. Recently, a diverse range of herbal monomers has emerged as a promising class of therapeutic agents for DKD. Compounds-including Anthocyanins, Morroniside, Resveratrol, Tanshinone, Puerarin, Baicalin, Curcumin, Protocatechuic acid, and Kaempferol-have been shown to activate the PPARγ and LXRα signaling pathways. This activation upregulates the expression of ABCA1 and ABCG1, thereby enhancing cholesterol efflux, mitigating renal lipid deposition, and ultimately slowing DKD progression. However, this body of research is largely limited to preclinical studies

Indexed as

ABCA1cholesterol effluxdiabetic kidney diseasePPARstraditional Chinese medicine

Identifiers

PMID41377559
PMCPMC12685638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.